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Treatment of congenital aortic valve stenosis: 
impact of the Ross operation
The Ross operation (auto-transplantation of
the pulmonary valve into the aortic position) [1, 2]
has recently (1997) been introduced in our unit as
one of the options for the treatment of children
and young adults with aortic valve stenosis. We
therefore decided to perform a retrospective study
in order to assess the impact of this evolution in
surgical management. 
Goal: To evaluate the impact of the Ross oper-
ation, recently (1997) introduced in our unit, for
the treatment of patients with congenital aortic
valve stenosis.
Methods: The period from January 1997 to De-
cember 2000 was compared with the previous 5
years (1992–96). Thirty-seven children (<16 yrs)
and 49 young adults (16–50 yrs) with congenital
aortic valve stenosis underwent one of these treat-
ments: percutaneous balloon dilatation (PBD),
aortic valve commissurotomy, aortic valve replace-
ment and the Ross operation. The Ross operation
was performed in 16 patients, mean age 24.5 yrs
(range 9–46 yrs) with a bicuspid stenotic aortic
valve, 7/10 adults with calcifications, 2/10 adults
with previous aortic valve commissurotomy, 4/6
children with aortic regurgitation following PBD,
and 1/6 children who had had a previous aortic
valve replacement with a prosthetic valve and aor-
tic root enlargement.
Results: PBD was followed by death in two
neonates (fibroelastosis); all other children sur-
vived PBD. Although there were no deaths, PBD
in adults was recently abandoned, owing to un-
favourable results. Aortic valve commissurotomy
showed good results in children (no deaths). Aor-
tic valve replacement, although associated with
good results (no deaths), has been recently aban-
doned in children in favour of the Ross operation.
Over a mean follow-up of 16 months (2–40
months) all patients are asymptomatic following
Ross operation, with no echocardiographic evi-
dence of aortic valve regurgitation in 10/16 pa-
tients and with trivial regurgitation in 6/16 pa-
tients.
Conclusions: The approach now for children
and young adults with congenital aortic valve
stenosis should be as follows: (1) PBD is the first
choice in neonates and infants; (2) Aortic valve
commissurotomy is the first choice for children,
neonates and infants after failed PBD; (3) The Ross
operation is increasingly used in children after
failed PBD and in young adults, even with a calci-
fied aortic valve.
Keywords: aortic valve stenosis; aortic valve commis-
surotomy; aortic valve replacement; congenital heart
defect; heart surgery; Ross operation
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Summary
Introduction
Materials and methods
All medical records of patients treated for congenital
aortic valve stenosis were reviewed, with the only exclu-
sion criteria being an age of over 50 years. The patients
were divided into groups of children (<16 years) and young
adults (16-50 years). They all underwent one (or more) of
four types of treatment: percutaneous balloon dilatation
(PBD), aortic valve commissurotomy, aortic valve re-
placement and the Ross operation. All patients were
grouped according to the last treatment received. Since
the Ross operation was introduced in our unit in 1997, we
arbitrarily decided to analyse the period from January
1997 to December 2000 and compare it with the preced-
ing five year period (1992–1996).
Table 1 summarises the treatment received by 20
children and 30 young adults during the earlier period
(1992–1996) and by 17 children and 19 young adults dur-
ing the latter period (1997–2000). Among the 16 patients
(6 children and 10 young adults – mean age 24.5 years,
range 9–46 years) who underwent a Ross operation for a
stenotic bicuspid aortic valve, 4 children presented with
aortic regurgitation post-PBD (after 1, 9, 9 and 10 years),
one child with previous aortic valve replacement with
prosthetic valve and aortic root enlargement (6 years be-
fore), 7/10 adults with calcifications of the aortic valve, and
2/10 adults with a previous aortic valve commissurotomy
(after 7 and 23 years). In one young adult patient the pul-
monary valve used for the autotransplantation into the
aortic position was a bicuspid valve, first detected at the
intraoperative transoesophageal echocardiography. In all
these patients the Ross operation was performed as aortic
root replacement (Fig. 1). The autotransplanted pul-
monary valve was replaced in the first 6 patients of our se-
ries with a conventional pulmonary homograft, in the last
10 cases with a new biological valved conduit constituted
from gluteraldehyde preserved bovine jugular vein (Con-
tegra).
The mean duration of cardiopulmonary bypass was
170 minutes (range 126–215 min), the mean duration of
aortic X-clamping was 98 minutes (range 80–124 min). In
all patients myocardial protection was accomplished with
antegrade blood cardioplegia at the beginning, and con-
tinuous retrograde blood cardioplegia through the coro-
nary sinus during the entire duration of the aortic X-
clamping.
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Period age percutaneous aortic valve aortic valve Ross
balloon dilatation commissurotomy replacement operation
1992–1996 <16 years 10 7 3 –
16–50 years 5 0 25 –
1997–2000 <16 years 5 6 0 6
16–50 years 0 0 9 10
Table 1
Patient
characteristics.
Figure 1
A. Intraoperative
photograph of the
diseased native aor-
tic valve in a child
who underwent the
Ross procedure at 
9 years of age, after
previous pulmonary
balloon dilatation at
5 months of age. 
B. Intraoperative
photograph of the
same child during
implantation of the
pulmonary autograft
(Ross operation) with
the root replacement
technique, with reim-
plantation of the
coronary arteries.
Results
Percutaneous balloon dilatation
The first two neonates, in the initial period,
undergoing PBD because of critical aortic steno-
sis, died. Autopsy showed a severe degree of left
ventricular fibroelastosis in both. All the other
children survived PBD, with 4/13 having under-
gone a Ross operation respectively after 1, 9, 9 and
10 years. 
Although none died, PBD in adults was re-
cently abandoned owing to unfavourable results:
all 5 young adults who underwent PBD in the first
period, required aortic valve replacement within
the 2 years of follow-up. 
Aortic valve commissurotomy
Good results were obtained in all 13 children,
with no deaths and no need for re-operation. Aor-
tic valve commissurotomy has never been per-
formed in adults in our department.
Aortic valve replacement
In children, despite good results (no deaths,
one re-operation after 6 years because the child
outgrew the prosthesis), the aortic valve replace-
ment has recently been abandoned in favour of the
Ross operation. In young adults with an indication
for aortic valve replacement (despite good results
with no deaths and no re-operation), the Ross op-
eration has increasingly been taken into consider-
ation as an alternative surgical option. 
Ross operation
In a mean follow-up of 16 months (2–40
months) all patients are alive, asymptomatic, with-
out need for cardiac medication or anticoagula-
tion, and have not required further interventions.
Echocardiography prior to discharge showed ab-
sence of aortic valve regurgitation in 10/16 pa-
tients and a trivial or mild degree of aortic valve
regurgitation in 6/16 patients (Fig. 2). At the last
echocardiographic follow-up, those without re-
A B
gurgitation had not developed any, and there 
was no progression of aortic valve regurgitation
amongst the others.
At the last echocardiographic control the fol-
lowing pressure gradients were measured across
the newly constructed right ventricular outflow
tract: peak gradient = 21 ± 3 mm Hg, mean gradi-
ent 11 ± 2 mm Hg. In none of the cases could more
than a trivial degree of pulmonary valve regurgita-
tion be detected.
No arrhythmias occurred during the periop-
erative period and all patients were in sinus rhythm
at the last follow-up.
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Figure 2
Postoperative
echocardiography 
of the same patient
(see Fig. 1), showing
mild aortic valve 
regurgitation, one
week after surgery.
Discussion
In 1967 [1] Ross described the use of the pa-
tient’s own pulmonary valve to replace the diseased
aortic and mitral valves. The new technique was
considered too complex by the surgical community
and was relegated to simple curiosity in the sur-
gical armamentarium. In 1988, however, the re-
ported long-term results of Ross’s experience [2]
with the pulmonary autograft in the aortic position
encouraged an increasing number of surgeons
around the world to initiate a series of this proce-
dure. Since then more and more Ross operations
have been performed, showing not only its feasi-
bility, but more importantly, its advantages [3, 4]:
– superior haemodynamic performance com-
pared to any other aortic valve replacement
method, because of the ideal “effective orifice
area” of the native pulmonary valve;
– very low thrombogenicity, with no require-
ment for anticoagulant therapy;
– demonstrable growth potential in the paedi-
atric age-group;
– expected durability;
– active lifestyle.
The number of Ross operations performed
worldwide has increased significantly in the last
decade, as shown in the International Registry for
the Ross procedure [5], with more than 500 pro-
cedures per year within the last 5 years.
The recent literature reviewed the anatomical
basis allowing for the performance of the Ross op-
eration [6], the use of different surgical techniques
[7–9] and the results obtained by units with initial
experience with this surgical procedure [10–12] as
well as by more established centers evaluating the
Ross operation as valve re-replacement [13].
Indication for operation
A Ross operation with pulmonary autograft
may be considered whenever replacement of the
aortic valve is indicated. The expected durability,
the very low thrombogenicity (no requirement for
anticoagulant therapy) and the superior haemody-
namic performance compared to any other aortic
valve replacement method, would encourage the
use of pulmonary autografts in young adults with
an active lifestyle, women planning pregnancy and
in patients with contraindications to treatment
with warfarin [14, 15].
Rheumatic aortic valve disease, previously
considered a contraindication for the Ross opera-
tion, has been treated with pulmonary autografts
with good results in a large number of patients
[16]. Some caution is required in young patients
during the active phase of rheumatic disease and in
the presence of severe concomitant mitral valve re-
gurgitation.
Because of the demonstrable growth potential
of pulmonary autografts implanted in the paedi-
atric age-group [17–19], the indication for the
Ross operation has been extended to early infancy
for both simple and complex left ventricular out-
flow tract obstructions [20].
Contraindications for the Ross operation
– Primary abnormalities of the pulmonary valve.
When there is significant regurgitation of the
pulmonary valve in preoperative surface or
transoesophageal echocardiography its use as
an aortic valve replacement should be discour-
aged. The use of a competent bicuspid pul-
monary valve is controversial. In our experi-
ence we have on one occasion used a bicuspid
pulmonary valve, detected at intraoperative
transoesophageal echocardiography, demon-
strating good functioning at the first post-
operative echocardiographic control.
– Iatrogenic lesions of the pulmonary valve. Pul-
monary valves injured during excision from
the right ventricular outflow tract should not
be utilized.
– Marfan syndrome. It is considered a contra-
indication for using pulmonary autografts
because of the abnormal structural morphol-
ogy of the pulmonary valve.
– Autoimmune tissue diseases. Like other connec-
tive tissue disorders, systemic lupus erythe-
matosus and rheumatoid arthritis are contra-
indications for the use of pulmonary auto-
grafts.
Results 
In large series [2–5, 11, 12, 16, 20] and in the
International Registry for the Ross procedure [5]
a relatively low early (3.5%) and late (<2%) mor-
tality has been reported. These results compared
with the conventional aortic valve replacement
with mechanical or biological prostheses, favour
the Ross operation, despite its technical complex-
ity and its limited tolerance of errors. In our expe-
rience we had no early or late deaths in the initial
group of 16 patients.
Re-operation
Ross reported 33 re-operations in 399 patients
followed for 24 years [21], with 19 patients re-op-
erated for technical problems with valve insertion
early in the experience, when the surgical tech-
nique used the sub-coronary valve replacement
method. With the current technique of aortic root
replacement, adopted since the beginning of our
experience, the technical problems should be a less
prominent cause for re-operation.
Dilatation of the neo-aortic annulus, with sub-
sequent aortic valve regurgitation, was the most
frequent cause for re-operation [3–5, 7–9, 21].
This problem occurred more frequently when the
Ross operation was performed for aortic valve
regurgitation than in aortic valve stenosis, and
technical modifications have been introduced to
achieve external fixation of the new aortic annulus
thereby preventing this problem [4, 5, 7, 8, 22].
Nevertheless the International Registry reports
absence of this problem for autograft reoperation
in 97% of patients at 5 years [5].
The second commonest cause for re-operation
is the pulmonary homograft replacement, particu-
larly in the paediatric population, where a small
homograft is inserted initially. In the large popu-
lation reported in the International Registry for
the Ross procedure [5] the need for pulmonary ho-
mograft replacement is currently 1.5% at 5 years.
In the last 10 pulmonary valve replacement pa-
tients of our experience, we used a new biological
valved conduit constituted by a gluterhaldeheyde
preserved bovine jugular vein (Contegra). The
preliminary results of this type of conduit are en-
couraging and have also been reported after im-
plantation for complex congenital heart defects
[23]. So far none of our patients have needed re-
operation in a mean follow-up of 16 months. 
Potential complications
Potential complications of a Ross operation
include the following:
– injury to the pulmonary autograft during
preparation/implantation; in this case the sur-
geon has to be ready to switch to the conven-
tional aortic valve replacement;
– injury to the left coronary artery, because of its
anatomical position; very accurate dissection is
required, possibly by a surgeon with experi-
ence in complex congenital heart surgery;
– poor myocardial protection, because of the
long aortic X-clamping time; in our experience
this complication has been avoided by the rou-
tine use of continuous retrograde blood car-
dioplegia through the coronary sinus, there-
fore avoiding myocardial ischaemia during the
entire duration of the aortic X-clamping;
– bleeding, because of adhesions in the case of
previous surgery, extensive dissection and long
duration of cardiopulmonary bypass; in our ex-
perience, thanks to very accurate dissection
and haemostasis immediately after every anas-
tomosis, together with the routine use of tis-
sue glue and aprotinine, chest re-opening be-
cause of bleeding was never required.
Conclusions
The preliminary results of the recent intro-
duction of the Ross operation in our unit, as a sur-
gical option to treat patients with congenital aor-
tic valve stenosis, have been encouraging, with no
early or late mortality, no re-operation, and more
than satisfactory aortic valve functioning.
As a result of this retrospective study, showing
a positive impact of the Ross operation in the man-
agement of patients with aortic valve stenosis, the
approach for treating children and young adults in
our unit with congenital aortic valve stenosis is
now as follows: (1) percutaneous balloon dilatation
is the first choice in neonates and infants; (2) aor-
tic valve commissurotomy is the first choice in chil-
dren, and in neonates and infants after failed per-
cutaneous balloon dilatation; (3) the Ross opera-
tion is increasingly used in children after failed
percutaneous balloon dilatation, in young adults,
even with calcified aortic valve, and particularly in
patients with an active lifestyle or women antici-
pating pregnancy.
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